Amendments to the Claims under 37 C.F.R. § 1.121

Claim 1 (currently amended): A method for isolating pluripotent progenitor cells having

stem cell-like characteristics of SSEA-4 and Tra-1-60 marker expression from a-human

mammary secretion of a male or female human body milk, wherein pluripotent cells are isolated

directly or indirectly from colostrum, mature milk, or dry period secretion during at least one

time period selected from the group consisting of a non-pregnant period, a pregnant period, a

lactating period, and an involuting period, wherein the whole human mammary secretion milk is

subjected to centrifugation, wherein following centrifugation the progenitor cells having stem-

cell like characteristics are separated from a cell pellet by suspending the cell pellet in a growth

medium and immuno-isolating the progenitor cells having stem-cell like characteristics with

magnetic beads and progenitor stem cell-specific antibodies.

Claim 2 (cancelled).

Claim 3 (currently amended): A method according to claim 1, wherein-said progenitor the

cells having stem-cell like characteristics are isolated from an acellular portion of the mammary

secretion milk that is separated from a cellular portion.

Claim 4 (cancelled).

Claim 5 (currently amended): A method according to claim 1, wherein human secretory

epithelial cells and leucocytes, and microorganisms are removed from the mammary secretion

milk.

Claim 6 (currently amended): A method according to claim 1, wherein progenitor the

cells having stem-cell like characteristics are isolated from mammary secretions milk isolated

during lactating periods wherein said lactating periods are selected from the group consisting of

the period after beginning of individual feeding, and the early lactation period.

2

Claim 7 (cancelled).

Claim 8 (currently amended): A method according to claim 1, wherein in a first step cellular components are washed out of the mammary secretion milk and retained, in a second step said cellular components are stained with antibodies to the progenitor stem cell markers, and in a third step the progenitor cells having stem-cell like characteristics are separated from the other cells directly or indirectly by means of the attached antibodies.

Claim 9 (currently amended): A method according to claim 8, wherein the antibody-stained progenitor-cells having stem-cell like characteristics are attached to beads and the progenitor-cells having stem-cell like characteristics are isolated using said beads, wherein when said beads are small iron beads, said beads are isolated using a magnet, and wherein subsequently the beads or the antibodies or both are removed from the progenitor-cells having stem-cell like characteristics.

Claim 10 (previously presented): A method according to claim 9, wherein the beads are removed using an enzyme selected from the group consisting of DNase, Proteinase, and RNase.

Claim 11 (currently amended): A method according to claim 1, wherein the <u>progenitor</u> cells <u>having stem-cell like characteristics</u> are cultured without using a fibroblast feeder layer.

Claim 12 (currently amended): A method according to claim 1, wherein in

- (i) a first step the whole human mammary secretion milk is subjected to centrifugation leaving a fat layer on top, a protein and carbohydrate rich supernatant beneath it, and at the bottom a pellet of cells;
 - (ii) in a second step the fat fraction and supernatant are removed;
- (iii) in a third step a volume of a buffer or cell culture media is added and the cells are resuspended in the buffer or media and centrifuged as in the first step and repeating this step 3 or

4 times, leaving a substantially pure cell pellet; and

(iv) in a fourth step separating the progenitor cells having stem cell-like characteristics from the cell pellet.

Claim 13 (currently amended): A method according to claim 12, wherein the progenitor cells having stem-cell like characteristics are separated from the cell pellet in that:

- (iv-1) the cell pellet is suspended in cell culture media;
- (iv-2) this suspension is incubated for 15 minutes at 4°C with progenitor cell-specific or stem cell-specific antibodies linked to magnetic beads via a small strand of DNA;
- (iv-3) a magnet is positioned in proximity to the suspension, whereby cells <u>having stem-cell like characteristics</u> that have bound to the magnetic beads attract the <u>progenitor</u> cells connected with the beads to the magnet, whereas unbound cells are not attracted by the magnet and remain in the supernatant; and
- (iv-4) the supernatant is removed, leaving only the <u>progenitor</u>-cells <u>having stem-cell like</u> <u>characteristics</u> bound to the beads via the <u>progenitor stem cell-specific antibody antibodies</u>.

Claim 14 (currently amended): A method according to claim 13, wherein thereafter:

- (v) <u>progenitor-cells having stem-cell like characteristics</u> bound to the beads via the stem cell-specific antibodies are removed by a cleavage means, wherein when the antibody is attached to the beads via small strand of DNA, said cleavage means is a DNase,
- (vi) the beads are removed by positioning the magnet to attract the beads, no longer attached to the stem-cells having stem-cell like characteristics, to it; and
- (vii) removing the supernatant containing the isolated progenitor-cells having stem-cell like characteristics.

Claim 15 (previously presented): A method according to claim 1, wherein the cells, following centrifugation, are incubated in a growth media that is permissive for growth of progenitor cells, stem cells or lactocyte growth.

Claim 16 (currently amended): A method according to claim 15, wherein in

(i) a first step the unfractionated human mammary secretion milk is subjected to centrifugation leaving a fat layer on top, a protein and carbohydrate rich supernatant beneath it, and at the bottom a pellet of cells;

(ii) in a second step, the cell pellet is washed in cell culture media;

(iii) in a third step the cells comprising the cell pellet are plated onto a cell culture vessel in bacteriocidal, fungicidal or both bacteriocidal and fungicidal growth media and incubated for 10-30 days and thereafter,

(iv) the cells are harvested and washed using buffer or growth media, and

(v) the harvested cells are plated onto a reconstituted basement membrane preparation.

Claim 17 (previously presented): A method according to claim 16, wherein in step (v) the solubulized basement membrane preparation is extracted from EHS mouse sarcoma.

Claims 18-24 (cancelled).

Claim 25 (new): The method of claim 1, wherein the cells are isolated directly or indirectly from colostrum or mature milk.

Claim 26 (new): The method of claim 1, wherein the cells are isolated during at least one time period that is selected from the group consisting of a non-pregnant period, a pregnant period, a lactating period, and an involuting period.